Grand Pharmaceutical introduces the world's first epinephrine nasal spray for the treatment of severe allergic reactions; China Energy Holdings is set to receive a full acquisition offer at a premium of approximately 9.03%, with trading resuming on December 24.
Material Events:
Kuaishou (01024): Strongly condemns illegal activities associated with black and gray industries, and has reported the case to the public security authorities and relevant departments.
Sinopharm Holdings (02096): SIM0610 (EGFR/cMET bispecific antibody-drug conjugate) has received clinical trial approval from the National Medical Products Administration.
Sinopec Engineering (Group) Corporation (02386) intends to acquire 100% equity of East China Pipeline Design Institute.
Grand Pharmaceutical (00512) introduces the world's first epinephrine nasal spray for the treatment of severe allergic reactions.
V立志博-B (09887): First subject dosed in Phase I trial of LBL-047.
Xinyi Energy (03868) plans to acquire all shares of Jinzhai Xinyi Wind Energy for RMB 62 million.
China Energy Holdings (00228) is proposed to receive a full acquisition offer at a premium of approximately 9.03%, with trading resuming on December 24.
Operating performance:
Cipni (02583) announced a profit alert, expecting annual net profit to increase year-on-year.
AEON CREDIT (00900) released its Q3 financial results, reporting a profit of HKD 353 million during the period, representing a year-on-year increase of 28.11%.
Sinohope Tech (01611) expects an annual net loss of no more than HKD 10 million.
